Abstract 1042P
Background
Clinical evidences of Immune checkpoint inhibitors (ICIs) plus antiangiogenic drugs as the first-line therapy for advanced non–small-cell lung cancer (NSCLC) were still insufficient, which greatly limited the application of evidence-based medicine in clinic. This study aimed to investigate the efficacy and safety of PD-1 inhibitors in combination with recombinant human endostatin (Rh-endostatin) and chemotherapy as the first-line treatment for advanced NSCLC.
Methods
Clinical data of 100 patients with NSCLC were retrospectively analyzed. Among them, 58 patients in the experimental group (IEC group) were treated with PD-1 inhibitors combined with Rh-endostatin and chemotherapy, and 42 patients treated with Rh-endostatin and chemotherapy were in the control group (EC group). The primary end point was progression-free survival (PFS), secondary end points included the objective response rate (ORR), disease control rate (DCR), and adverse events were compared between the IEC group and EC group.
Results
The IEC group showed significantly improved ORR (67.2% vs 42.9%, P = 0.015) and prolonged PFS (10.2 months vs 6.5 months, P < 0.001). The DCR and 1-year OS rate in the IEC group was higher than that in the EC group, while the difference was not statistically significant (98.3% vs 90.5%, P=0.193; 79.3% vs 76.2%, P=0.710). Cox multivariate regression analysis revealed that treatment modality, brain metastasis and clinical stage might be independent risk factors for median PFS (mPFS). There were no significant differences in adverse events between two groups.
Conclusions
Our study showed the superiority of combination therapy of PD-1 inhibitors combined with Rh-endostatin as first-line treatment for advanced NSCLC in terms of ORR and PFS, which represented a promising treatment modality for this population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Hongxiang Huang.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.